-
Je něco špatně v tomto záznamu ?
Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
E. Bolla, AG. Semb, AM. Kerola, E. Ikdahl, M. Petri, GJ. Pons-Estel, GA. Karpouzas, PP. Sfikakis, R. Quintana, DP. Misra, EF. Borba, I. Garcia-de la Torre, TV. Popkova, B. Artim-Esen, A. Troldborg, H. Fragoso-Loyo, S. Ajeganova, A. Yazici, G....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
- MeSH
- antifosfolipidový syndrom * epidemiologie komplikace MeSH
- dospělí MeSH
- hypertenze epidemiologie MeSH
- kardiovaskulární nemoci * epidemiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- prevalence MeSH
- průřezové studie MeSH
- rizikové faktory kardiovaskulárních chorob * MeSH
- rizikové faktory MeSH
- systémový lupus erythematodes * epidemiologie komplikace MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
BACKGROUND: Systemic lupus erythematosus (SLE) is characterised by increased cardiovascular morbidity and mortality risk. We aimed to examine the prevalence of traditional cardiovascular risk factors and their control in an international survey of patients with systemic lupus erythematosus. METHODS: In this multicentre, cross-sectional study, cardiovascular risk factor data from medical files of adult patients (aged ≥18) with SLE followed between Jan 1, 2015, and Jan 1, 2020, were collected from 24 countries, across five continents. We assessed the prevalence and target attainment of cardiovascular risk factors and examined potential differences by country income level and antiphospholipid syndrome coexistence. We used the Systemic Coronary Risk Evaluation algorithm for cardiovascular risk estimation, and the European Society of Cardiology guidelines for assessing cardiovascular risk factor target attainment. People with lived experience were not involved in the research or writing process. FINDINGS: 3401 patients with SLE were included in the study. The median age was 43·0 years (IQR 33-54), 3047 (89·7%) of 3396 patients were women, 349 (10.3%) were men, and 1629 (48·1%) of 3390 were White. 556 (20·7%) of 2681 patients had concomitant antiphospholipid syndrome. We found a high cardiovascular risk factor prevalence (hypertension 1210 [35·6%] of 3398 patients, obesity 751 [23·7%] of 3169 patients, and hyperlipidaemia 650 [19·8%] of 3279 patients), and suboptimal control of modifiable cardiovascular risk factors (blood pressure [target of <130/80 mm Hg], BMI, and lipids) in the entire SLE group. Higher prevalence of cardiovascular risk factors but a better blood pressure (target of <130/80 mm Hg; 54·9% [1170 of 2132 patients] vs 46·8% [519 of 1109 patients]; p<0·0001), and lipid control (75·0% [895 of 1194 patients] vs 51·4% [386 of 751 patients], p<0·0001 for high-density lipoprotein [HDL]; 66·4% [769 of 1158 patients] vs 60·8% [453 of 745 patients], p=0·013 for non-HDL; 80·9% [1017 of 1257 patients] vs 61·4% [486 of 792 patients], p<0·0001 for triglycerides]) was observed in patients from high-income versus those from middle-income countries. Patients with SLE with antiphospholipid syndrome had a higher prevalence of modifiable cardiovascular risk factors, and significantly lower attainment of BMI and lipid targets (for low-density lipoprotein and non-HDL) than patients with SLE without antiphospholipid syndrome. INTERPRETATION: High prevalence and inadequate cardiovascular risk factor control were observed in a large multicentre and multiethnic SLE cohort, especially among patients from middle-income compared with high-income countries and among those with coexistent antiphospholipid syndrome. Increased awareness of cardiovascular disease risk in SLE, especially in the above subgroups, is urgently warranted. FUNDING: None.
Departamento de Inmunología y Reumatología Hospital General de Occidente Jalisco Mexico
Department of Biomedicine Aarhus University Aarhus Denmark
Department of Clinical Medicine Aarhus University Aarhus Denmark
Department of Experimental and Clinical Medicine University of Florence Florence Italy
Department of Geriatric Medicine Division of Rheumatology and Scleroderma Unit AOUC Florence Italy
Department of Internal Medicine Division of Rheumatology Istanbul Bilim University Istanbul Türkiye
Department of Internal Medicine Facultad de Medicina Universidad de la República Montevideo Uruguay
Department of Internal Medicine Päijät Häme Central Hospital Lahti Finland
Department of Medicine Huddinge Karolinska Institutet Stockholm Sweden
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
Department of Rheumatology Monash Health Clayton VIC Australia
Department of Rheumatology Oslo University Hospital Oslo Norway
Department of Rheumatology Universidad Nacional de Asunción Asuncion Paraguay
Division of Rheumatology CARE Pain and Arthritis Centre Udaipur India
Division of Rheumatology Department of Medicine Solna Karolinska Institutet Stockholm Sweden
Division of Rheumatology Harbor UCLA Medical Center Torrance CA USA
Division of Rheumatology Johns Hopkins University School of Medicine Baltimore MD USA
Faculty of Medicine University of Helsinki Helsinki Finland
Grupo Oroño Centro Regional de Enfermedades Autoinmunes y Reumáticas Rosario Argentina
Institute of Rheumatology Prague Czech Republic
Kyrgyz State Medical Academy Bishkek Kyrgyzstan
Research Unit Argentine Society of Rheumatology Buenos Aires Argentina
Rheumatology and Clinical Immunology Unit ASST Spedali Civili Brescia Italy
Rheumatology Department Faculty of Medicine Demiroglu Bilim University Istanbul Türkiye
Rheumatology Department Hospital Nacional Guillermo Almenara Irigoyen EsSalud Lima Peru
Rheumatology Unit Azienda Ospedaliero Universitaria Pisana Pisa Italy
School of Clinical Science Monash University Clayton VIC Australia
Servicio de Reumatología Hospital Docente Padre Billini Santo Domingo Dominican Republic
The Lundquist Institute Torrance CA USA
Universidad de Guadalajara Guadalajara Jalisco Mexico
Universidad Simón Bolívar Barranquilla Colombia
VA Nasonova Research Institute of Rheumatology Moscow Russia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013339
- 003
- CZ-PrNML
- 005
- 20240905134415.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S2665-9913(24)00090-0 $2 doi
- 035 __
- $a (PubMed)38878780
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bolla, Eleana $u Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece
- 245 10
- $a Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries / $c E. Bolla, AG. Semb, AM. Kerola, E. Ikdahl, M. Petri, GJ. Pons-Estel, GA. Karpouzas, PP. Sfikakis, R. Quintana, DP. Misra, EF. Borba, I. Garcia-de la Torre, TV. Popkova, B. Artim-Esen, A. Troldborg, H. Fragoso-Loyo, S. Ajeganova, A. Yazici, G. Aroca-Martinez, H. Direskeneli, MF. Ugarte-Gil, M. Mosca, M. Goyal, E. Svenungsson, C. Macieira, A. Hoi, K. Lerang, N. Costedoat-Chalumeau, A. Tincani, E. Mirrakhimov, I. Acosta Colman, A. Danza, L. Massardo, J. Blagojevic, N. Yılmaz, D. Tegzová, S. Yavuz, C. Korkmaz, E. Hachulla, MJ. Moreno Alvarez, R. Muñoz-Louis, N. Pantazis, MG. Tektonidou, SURF-SLE and APS collaborators
- 520 9_
- $a BACKGROUND: Systemic lupus erythematosus (SLE) is characterised by increased cardiovascular morbidity and mortality risk. We aimed to examine the prevalence of traditional cardiovascular risk factors and their control in an international survey of patients with systemic lupus erythematosus. METHODS: In this multicentre, cross-sectional study, cardiovascular risk factor data from medical files of adult patients (aged ≥18) with SLE followed between Jan 1, 2015, and Jan 1, 2020, were collected from 24 countries, across five continents. We assessed the prevalence and target attainment of cardiovascular risk factors and examined potential differences by country income level and antiphospholipid syndrome coexistence. We used the Systemic Coronary Risk Evaluation algorithm for cardiovascular risk estimation, and the European Society of Cardiology guidelines for assessing cardiovascular risk factor target attainment. People with lived experience were not involved in the research or writing process. FINDINGS: 3401 patients with SLE were included in the study. The median age was 43·0 years (IQR 33-54), 3047 (89·7%) of 3396 patients were women, 349 (10.3%) were men, and 1629 (48·1%) of 3390 were White. 556 (20·7%) of 2681 patients had concomitant antiphospholipid syndrome. We found a high cardiovascular risk factor prevalence (hypertension 1210 [35·6%] of 3398 patients, obesity 751 [23·7%] of 3169 patients, and hyperlipidaemia 650 [19·8%] of 3279 patients), and suboptimal control of modifiable cardiovascular risk factors (blood pressure [target of <130/80 mm Hg], BMI, and lipids) in the entire SLE group. Higher prevalence of cardiovascular risk factors but a better blood pressure (target of <130/80 mm Hg; 54·9% [1170 of 2132 patients] vs 46·8% [519 of 1109 patients]; p<0·0001), and lipid control (75·0% [895 of 1194 patients] vs 51·4% [386 of 751 patients], p<0·0001 for high-density lipoprotein [HDL]; 66·4% [769 of 1158 patients] vs 60·8% [453 of 745 patients], p=0·013 for non-HDL; 80·9% [1017 of 1257 patients] vs 61·4% [486 of 792 patients], p<0·0001 for triglycerides]) was observed in patients from high-income versus those from middle-income countries. Patients with SLE with antiphospholipid syndrome had a higher prevalence of modifiable cardiovascular risk factors, and significantly lower attainment of BMI and lipid targets (for low-density lipoprotein and non-HDL) than patients with SLE without antiphospholipid syndrome. INTERPRETATION: High prevalence and inadequate cardiovascular risk factor control were observed in a large multicentre and multiethnic SLE cohort, especially among patients from middle-income compared with high-income countries and among those with coexistent antiphospholipid syndrome. Increased awareness of cardiovascular disease risk in SLE, especially in the above subgroups, is urgently warranted. FUNDING: None.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a systémový lupus erythematodes $x epidemiologie $x komplikace $7 D008180
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prevalence $7 D015995
- 650 12
- $a rizikové faktory kardiovaskulárních chorob $7 D000082742
- 650 12
- $a kardiovaskulární nemoci $x epidemiologie $7 D002318
- 650 12
- $a antifosfolipidový syndrom $x epidemiologie $x komplikace $7 D016736
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a hypertenze $x epidemiologie $7 D006973
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Semb, Anne Grete $u Preventive Cardio-Rheuma Clinic, Division of Research and Innovation, REMEDY Centre, Diakonhjemmet Hospital, Oslo, Norway
- 700 1_
- $a Kerola, Anne M $u Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland; Faculty of Medicine, University of Helsinki, Helsinki, Finland
- 700 1_
- $a Ikdahl, Eirik $u Preventive Cardio-Rheuma Clinic, Division of Research and Innovation, REMEDY Centre, Diakonhjemmet Hospital, Oslo, Norway
- 700 1_
- $a Petri, Michelle $u Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 700 1_
- $a Pons-Estel, Guillermo J $u Research Unit, Argentine Society of Rheumatology, Buenos Aires, Argentina
- 700 1_
- $a Karpouzas, George A $u Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, USA; The Lundquist Institute, Torrance, CA, USA
- 700 1_
- $a Sfikakis, Petros P $u Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece
- 700 1_
- $a Quintana, Rosana $u Grupo Oroño, Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina
- 700 1_
- $a Misra, Durga Prasanna $u Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
- 700 1_
- $a Borba, Eduardo Ferreira $u Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
- 700 1_
- $a Garcia-de la Torre, Ignacio $u Departamento de Inmunología y Reumatología, Hospital General de Occidente, Jalisco, Mexico; Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
- 700 1_
- $a Popkova, Tatiana V $u VA Nasonova Research Institute of Rheumatology, Moscow, Russia
- 700 1_
- $a Artim-Esen, Bahar $u Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Istanbul University, Istanbul, Türkiye
- 700 1_
- $a Troldborg, Anne $u Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Biomedicine, Aarhus University, Aarhus, Denmark
- 700 1_
- $a Fragoso-Loyo, Hilda $u Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- 700 1_
- $a Ajeganova, Sofia $u Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Sciences, Rheumatology Division, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
- 700 1_
- $a Yazici, Ayten $u Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Kocaeli University, Kocaeli, Türkiye
- 700 1_
- $a Aroca-Martinez, Gustavo $u Universidad Simón Bolívar, Barranquilla, Colombia
- 700 1_
- $a Direskeneli, Haner $u Division of Rheumatology, Department of Internal Medicine, Marmara University, School of Medicine, Istanbul, Türkiye
- 700 1_
- $a Ugarte-Gil, Manuel F $u Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Rheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru
- 700 1_
- $a Mosca, Marta $u Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
- 700 1_
- $a Goyal, Mohit $u Division of Rheumatology, CARE Pain and Arthritis Centre, Udaipur, India
- 700 1_
- $a Svenungsson, Elisabet $u Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a Macieira, Carla $u Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre, Lisboa, Portugal
- 700 1_
- $a Hoi, Alberta $u Department of Rheumatology, Monash Health, Clayton, VIC, Australia; School of Clinical Science, Monash University, Clayton, VIC, Australia
- 700 1_
- $a Lerang, Karoline $u Department of Rheumatology, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Costedoat-Chalumeau, Nathalie $u National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université Paris Cité, Paris, France
- 700 1_
- $a Tincani, Angela $u Rheumatology and Clinical Immunology Unit-ASST Spedali Civili, Brescia, Italy
- 700 1_
- $a Mirrakhimov, Erkin $u Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan
- 700 1_
- $a Acosta Colman, Isabel $u Department of Rheumatology, Universidad Nacional de Asunción, Asuncion, Paraguay
- 700 1_
- $a Danza, Alvaro $u Department of Internal Medicine, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
- 700 1_
- $a Massardo, Loreto $u Centro de Biología Celular y Biomedicina, Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile
- 700 1_
- $a Blagojevic, Jelena $u Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Department of Geriatric Medicine, Division of Rheumatology and Scleroderma Unit, AOUC, Florence, Italy
- 700 1_
- $a Yılmaz, Neslihan $u Rheumatology Department, Faculty of Medicine, Demiroglu Bilim University, Istanbul, Türkiye
- 700 1_
- $a Tegzová, Dana $u Institute of Rheumatology, Prague, Czech Republic
- 700 1_
- $a Yavuz, Sule $u Department of Internal Medicine, Division of Rheumatology, Istanbul Bilim University, Istanbul, Türkiye
- 700 1_
- $a Korkmaz, Cengiz $u Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Türkiye
- 700 1_
- $a Hachulla, Eric $u Department of Internal Medicine and Clinical Immunology, National Referral Centre for Rare Systemic Auto-Immune and Auto-inflammatory Diseases, University of Lille, Inserm, CHU Lille, U1286 - INFINITE, University of Lille, Lille, France
- 700 1_
- $a Moreno Alvarez, Mario J $u Servicio Reumatología, Hospital Luis Vernaza, Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador
- 700 1_
- $a Muñoz-Louis, Roberto $u Servicio de Reumatología, Hospital Docente Padre Billini, Santo Domingo, Dominican Republic
- 700 1_
- $a Pantazis, Nikos $u Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Tektonidou, Maria G $u Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece. Electronic address: mtektonidou@med.uoa.gr
- 710 2_
- $a SURF-SLE and APS collaborators
- 773 0_
- $w MED00214733 $t The Lancet. Rheumatology $x 2665-9913 $g Roč. 6, č. 7 (2024), s. e447-e459
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38878780 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905134409 $b ABA008
- 999 __
- $a ok $b bmc $g 2143260 $s 1225205
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 6 $c 7 $d e447-e459 $e 20240612 $i 2665-9913 $m The Lancet. Rheumatology $n Lancet Rheumatol $x MED00214733
- LZP __
- $a Pubmed-20240725
